RELIEF THERAPEUTICS Holding SA

"Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 16.05.2025/nPublicly viewable until: 16.05.2027/nPublication number: UP04-0000007196/nPublishing entity/nRELIEF THERAPEUTICS Holding SA, avenue de Sécheron 15.

1202 Genève/nInvitation to the ordinary general meeting RELIEF/nTHERAPEUTICS Holding SA/nOrganisation concerned:
/nRELIEF THERAPEUTICS Holding SA/nCHE-113.516.874/navenue de Sécheron 15/n1202 Genève/nGeneral meeting details:/n12.06.2025, 10.00 Uhr, Campus Biotech, avenue de Sécheron 15.

1202 Genève/nInvitation/Agenda:
/n1 Approval of the 2024 Annual Report, the Annual Statutory Financial Statements, and/nthe Annual Consolidated Financial Statements for the 2024 Financial Year/n2 Appropriation of Available Earnings/n3 Discharge of the Board of Directors and the Executive Committee/n4.1 Re-elections of the members of the Board of Directors/n4.2 Re-election of the Chairman of the Board of Directors/n4.3 Re-elections of the members of the Nomination and Compensation Committee/n5.1 Vote on the compensation of the Board of Directors/n5.2 Vote on the total compensation of the Executive Committee/n5.3 Consultative vote on the 2024 Compensation Report/n 6 Re-election of the Independent Voting Rights Representative/n 7 Re-election of the Auditors/n To the shareholders of RELIEF THERAPEUTICS Holding SA:/n Invita on to the Annual General Mee ng/n of RELIEF THERAPEUTICS Holding SA/n Thursday, 12 June 2025.

10:
00 a.m. CEST/n Avenue de Sécheron 15, 1202 Geneva, Switzerland/n The Annual General Mee ng (the ""General Mee ng"") of shareholders of RELIEF THERAPEUTICS Holding SA/n (the ""Company"") will be held in accordance with Ar cle 9 et seq. of the Ar cles of Associa on on Thursday,/n 12 June 2025.

at 10:
00 a.m. CEST, at Avenue de Sécheron 15, 1202 Geneva, Switzerland (doors open at/n 09:30 a.m.)./n Agenda and Proposals of the Board of Directors/n1. Approval of the 2024 Annual Report, the Annual Statutory Financial Statements, and the Annual/n Consolidated Financial Statements for the 2024 Financial Year/n The Board of Directors proposes that the General Mee ng approve the 2024 annual report, the statutory/n financial statements, and the consolidated financial statements for the 2024 financial year./n Explana on: Pursuant to ar cle 698 para. 2 items 3 and 4 of the Swiss Code of Obliga ons (""CO""), the/n General Mee ng is responsible for approving the annual report and the financial statements./n2. Appropria on of Available Earnings/n The Board of Directors proposes to carry forward the net result for the 2024 financial year of CHF 916'291,/n thereby bringing the accumulated loss to CHF 257'968'557./n Explana on: Pursuant to ar cle 698 para. 2 item 4 CO, the General Mee ng is responsible for the/n appropria on of available earnings./n3. Discharge of the Board of Directors and the Execu ve Commi ee/n The Board of Directors proposes that the General Mee ng grant discharge to all current and former/n members of the Board of Directors and the Execu ve Commi ee for the 2024 financial year./n Explana on: Pursuant to ar cle 698 para. 2 item 7 CO, the General Mee ng is responsible for the discharge/n resolu on./n4. Elec ons to the Board of Directors/n 4.1.

Re-elec ons of the members of the Board of Directors/n The Board of Directors proposes the individual re-elec on of all members of the Board of Directors for/n another term of office un l the conclusion of the next Annual General Mee ng, as follows:
/n a) Re-elec on of Dr. Raghuram Selvaraju/n b) Re-elec on of Mr. Gregory Van Beek/n c) Re-elec on of Mr. Peter de Svas ch/n d) Re-elec on of Mr.

Thomas Elzinga/n Explana on:
Pursuant to ar cle 698 para. 2 item 2 CO, the General Mee ng is responsible for the elec ons/n of the members of the Board of Directors. Biographical informa on is available in the 2024 annual report/n and on the Company's website./n 4.2. Re-elec on of the Chairman of the Board of Directors/n The Board of Directors proposes the re-elec on of Dr. Raghuram Selvaraju as Chairman of the Board of/n Directors for another term of office un l the conclusion of the next Annual General Mee ng./n Explana on: Pursuant to ar cle 698 para. 3 item 1 CO, the General Mee ng is responsible for the above/n elec on./n 4.3.

Re-elec ons of the members of the Nomina on and Compensa on Commi ee/n The Board of Directors proposes the individual re-elec on of the members of the Nomina on and/n Compensa on Commi ee for another term of office un l the conclusion of the next Annual General/n Mee ng, as follows:
/n a) Re-elec on of Mr. Peter de Svas ch/n b) Re-elec on of Dr.

Raghuram Selvaraju/n Explana on:
Pursuant to ar cle 698 para. 3 item 2 CO, the General Mee ng is responsible for the above/n elec on. The elec ons of the members of the Nomina on and Compensa on Commi ee are held/n individually./n5. Compensa on of the Board of Directors and the Execu ve Commi ee/n 5.1. Binding vote on the total compensa on of the members of the Board of Directors for the period/n from the 2025 Annual General Mee ng un l the 2026 Annual General Mee ng/n The Board of Directors proposes the approval of a maximum total compensa on of CHF 1'000'000 (fixed/n and variable components, including stock op ons and other benefits, excluding employer social security/n contribu ons) for the members of the Board of Directors for the period from this 2025 Annual General/n Mee ng un l the 2026 Annual General Mee ng./n Explana on: Pursuant to ar cle 698 para. 3 item 4 CO, the General Mee ng is responsible for approving/n the maximum compensa on of the Board of Directors. The compensa on of the Board of Directors is/n determined based on discre onary economic considera ons and may be delivered in cash and in the form/n of op ons. A descrip on of the Company's compensa on principles and amounts for the members of the/n Board of Directors can be found in the 2024 compensa on report./n 5.2. Binding vote on the total compensa on of the members of the Execu ve Commi ee for the 2026/n Financial Year/n The Board of Directors proposes the approval of a maximum total compensa on of CHF 2'000'000 (fixed/n and variable components, including stock op ons and other benefits, excluding employer social security/n contribu ons) for the members of the Execu ve Commi ee for the 2026 financial year./n Explana on: Pursuant to ar cle 698 para. 3 item 4 CO, the General Mee ng is responsible for approving the/n maximum compensa on of the Execu ve Commi ee. The compensa on of the members of the Execu ve/n Commi ee consists of fixed compensa on, poten al variable compensa on, and other benefits. A/n descrip on of the Company's compensa on principles and amounts for the members of the Execu ve/n Commi ee can be found in the 2024 compensa on report./n 5.3. Consulta ve vote on the 2024 Compensa on Report/n The Board of Directors proposes that the General Mee ng approve, on a consulta ve basis, the/n compensa on report for the 2024 financial year./n Explana on: Pursuant to ar cle 735 para. 3 item 4 CO, the Board of Directors submits the compensa on/n report to the General Mee ng for a consulta ve vote./n6. Re-elec on of the Independent Vo ng Rights Representa ve/n The Board of Directors proposes the re-elec on of Mr. Thomas Hua, esq., partner at gbf Avocats SA, Route/n de Pré-Bois 20, 1215 Genève Aéroport, Switzerland, as independent proxy of the Company for another term/n of office un l the conclusion of the next Annual General Mee ng./n Explana on: Pursuant to ar cle 698 para. 3 item 3 CO, the General Mee ng is responsible for the above/n elec on. Mr. Thomas Hua fulfills the legal requirements and is available for elec on./n7. Re-elec on of the Auditors/n The Board of Directors proposes the re-elec on of FORVIS MAZARS SA, Geneva, as the Company's statutory/n auditors for another term of office un l the conclusion of the next Annual General Mee ng./n Explana on: Pursuant to ar cl"

"Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 03.06.2024/nPublicly viewable until: 03.06.2026/nPublication number: UP04-0000006372/nPublishing entity/nRELIEF THERAPEUTICS Holding SA, avenue de Sécheron 15.

1202 Genève/nInvitation to the ordinary general meeting RELIEF/nTHERAPEUTICS Holding SA/nOrganisation concerned:
/nRELIEF THERAPEUTICS Holding SA/nCHE-113.516.874/navenue de Sécheron 15/n1202 Genève/nGeneral meeting details:/n27.06.2024, 11.00 Uhr, Campus Biotech, chemin des Mines 9.

1202 Genève/nInvitation/Agenda:
/n1. Approval of the Annual Report 2023, Statutory Financial Statements and Consolidated/nFinancial Statements for the Financial Year 2023/n2. Appropriation of Results/n3. Discharge of the Board of Directors and the Executive Committee/n4.1 Vote on the compensation of the Board of Directors/n4.2 Vote on the remuneration of the Executive Committee/n4.3 Consultative vote on the 2023 Compensation Report/n5.1 Re-election of the current members of the Board of Directors/n5.2 Re-election of the Chairman of the Board of Directors/n5.3 Re-election and election of new members of the Nomination and Compensation/nCommittee/n5.4 Re-election of the Independent Voting Rights Representative/n5.5 Re-election of the Auditors/nTo the Shareholders of RELIEF THERAPEUTICS Holding SA:/nInvitation to the Annual Shareholders' Meeting/nof RELIEF THERAPEUTICS Holding SA/nThursday, 27 June 2024.

11:
00 a.m. CEST (door opening: 10:30 a.m. CEST)/nat Campus Biotech, chemin des Mines 9, 1202 Geneva, Switzerland/nThe Annual General Meeting of Shareholders of RELIEF THERAPEUTICS Holding SA (the ""Company"") will be/nheld in accordance with article 9 and subsequent articles of the Articles of Association on Thursday, 27 June/n2024.

at 11:
00 a.m. CEST at Campus Biotech, chemin des Mines 9, 1202 Geneva, Switzerland./nAgenda Items and Proposals of the Board of Directors/n1. Approval of the Annual Report 2023, Statutory Financial Statements and Consolidated/nFinancial Statements for the Financial Year 2023/nThe Board of Directors proposes the approval of the annual report 2023, the statutory financial statements/nand the consolidated financial statements for the financial year 2023./nExplanation: Pursuant to article 698 para. 2 al. 3 and 4 of the Swiss Code of Obligations (""CO""), the General/nMeeting is responsible for approving the annual report, the statutory financial statements and the/nconsolidated financial statements./n2. Appropriation of Results/nThe Board of Directors proposes to carry forward the loss for the financial year 2023 of CHF 39'943'547./nExplanation: Pursuant to article 698 para. 2 al. 4 CO, the General Meeting is responsible for the/nappropriation of results./n3. Discharge of the Board of Directors and the Executive Committee/nThe Board of Directors proposes that the General Meeting grants discharge to all current and former/nmembers of the Board of Directors and of the Executive Committee for the financial year 2023./nExplanation: Pursuant to article 698 para. 2 al. 7 CO, the General Meeting is responsible for the discharge/nresolution. The resolution for discharge presented to this General Meeting for the financial year 2023 serves/nas a supplementary action. It follows the initial discharge granted by the Extraordinary General Meeting/nheld on 26 April 2024, which occurred prior to the publication of the Company's 2023 annual report./n4. Votes on the compensation of the members of the Board of Directors and of the Executive/nCommittee/nThe Board of Directors proposes a separate vote on the compensation of the Board of Directors and of the/nExecutive Committee. The 2023 compensation report is included in the 2023 annual report, which can be/naccessed on the Company's website at www.relieftherapeutics.com./n4.1. Binding vote on the total compensation of the members of the Board of Directors for the period/nfrom the Annual General Meeting 2024 until the Annual General Meeting 2025/nThe Board of Directors proposes the approval of a maximum amount of CHF 1'000'000 (both fixed and/nvariable compensation, including stock options and other benefits, but excluding employer social security/ncontributions) for the members of the Board of Directors for the period from the Annual General Meeting/n2024 until the Annual General Meeting 2025./nExplanation: Pursuant to article 698 para. 3 al. 4 CO, the General Meeting is responsible for approving the/nmaximum compensation of the Board of Directors. The compensation of the Board of Directors is/ndetermined based on discretionary economic considerations and may be delivered in cash and in the form/nof options. A description of the Company's compensation principles and amounts for the members of the/nBoard of Directors can be found in the 2023 compensation report./n4.2. Binding vote on the total remuneration of the members of the Executive Committee for the financial/nyear 2025/nThe Board of Directors proposes the approval of a maximum total compensation of CHF 4'000'000 (both/nfixed and variable compensation, including stock options and other benefits, but excluding employer social/nsecurity contributions) for the members of the Executive Committee for the financial year 2025./nExplanation: Pursuant to article 698 para. 3 al. 4 CO, the General Meeting is responsible for approving the/nmaximum remuneration of the Executive Committee. The compensation of the members of the Executive/nCommittee consists of a fixed remuneration, a potential variable remuneration, and other benefits. A/ndescription of the Company's compensation principles and amounts for the members of the Executive/nCommittee can be found in the 2023 compensation report./n4.3. Consultative vote on the 2023 Compensation Report/nThe Board of Directors proposes that the General Meeting approves, on a consultative basis, the/ncompensation report for the financial year 2023./nExplanation: Pursuant to article 735 para. 3 al. 4 CO, the Board of Directors submits the compensation/nreport to the General Meeting for a consultative vote./n5. Elections/n5.1. Re-election of the current members of the Board of Directors/nThe Board of Directors proposes the re-election of the following members of the Board of Directors for/nanother term of office that will end for all members with the closure of the next Annual General Meeting./nThe re-elections will be held individually./na) Re-election of Dr. Raghuram Selvaraju/nb) Re-election of Ms. Michelle Lock/nc) Re-election of Mr. Peter de Svastich/nd) Re-election of Mr. Gregory Van Beek/ne) Re-election of Mr.

Thomas Elzinga/nExplanation:
Pursuant to article 698 para. 2 al. 2 CO, the General Meeting is responsible for the elections of/nthe members of the Board of Directors. Biographical details on the candidates are provided in the 2023/nannual report and on the Company's website at www.relieftherapeutics.com./n5.2. Re-election of the Chairman of the Board of Directors/nThe Board of Directors proposes the re-election of Dr. Raghuram Selvaraju as Chairman of the Board of/nDirectors for a term of office that will end with the closure of the next Annual General Meeting./nExplanation: Pursuant to article 698 para. 3 al. 1 CO, the General Meeting is responsible for the above/nelection./n5.3. Re-election and election of new members of the Nomination and Compensation Committee/nThe Board of Directors proposes the election of Mr. Peter de Svastich and the re-election of Dr. Raghuram/nSelvaraju as members of the Nomination and Compensation Committee for a term of office which will end/nwith the closure of the next Annual General Meeting. The elections will be held individually./nExplanation: Pursuant to article 698 para. 3 al. 2 CO, the General Meeting is responsible for the above/nelection. The elections of the members of the Nomination and Compensation Committee are held/nindividually./n5.4. Re-election of the Independent Voting Rights Representative/nThe Board of Directors proposes the re-election of Mr. Thomas Hua, esq., partner at gbf Avocats SA, Route/nde Pré-Bois 20, 1215 Genève Aéroport, Switzerland, as independent proxy holder of the Company for the/nnext term "